Seeking Alpha·3d ago
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring TranscriptADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript
ADC Therapeutics appears to be trading revenue stagnation for expense discipline: year-over-year revenue growth of just 2.2% in 2026Q2 masks a 42% reduction in R&D spend (from $30.1M in 2025Q2 to $17.4M), which narrowed operating losses from $44.1M to $25.4M but leaves gross profit of $16.9M still well below the $39.7M…
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.11+49.1% vs -$0.22 | $19M+1.9% vs $19M |
Q2 2026 May 4, 2026 | -$0.21-10.5% vs -$0.19 | $21M+4.3% vs $20M |
Q2 2026 Mar 10, 2026 | -$0.04+87.5% vs -$0.32 | $23M+3.4% vs $22M |
Q4 2025 Nov 10, 2025 | -$0.30+25.0% vs -$0.40 | $16M-2.2% vs $17M |
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Data at ASH and Strategic Financial Restructuring Transcript
ADC Therapeutics NYSE: ADCT outlined new lymphoma data and plans for further studies of its cancer drug ZYNLONTA, while reporting preliminary third-quarter sales of approximately $21 million and an expected cash runway into 2029.
ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r DLBCL patients Phase 2 marginal zone lymphoma IIT abstract shows robust and durable 93% ORR and 74.4% CRR with ZYNLONTA monotherapy Company to host conference call today at 4:15 p.m. EST LAUSANNE, Switzerland, Nov. 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced new and updated data from the ZYNLONTA® (loncastuximab tesirine-lpyl) clinical program will be shared across multiple abstracts, including five oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana.
LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences in November: Guggenheim Third Annual Healthcare Innovation Conference Date: Tuesday, November 10, 2026Presentation Time: 1:30 p.m. ESTFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive OfficerLocation: Boston, MATo register for the webcast, click here.
Benchmark ADCT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ADC Therapeutics S.A. (ADCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.58 | $200.96M | -2.53 | 14.85% | -123.03% | — | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $2.33 | $148.1M | -10.15 | 0.78% | -8.7% | -31.27% | — | |
| $291.31 | $514.68B | 49.87 | 8.57% | 15.68% | — | 2.26% | |
| $29.39 | $167.51B | 41.91 | -1.65% | 6.34% | 4.58% | 5.85% | |
| $2.50 | $394.97K | -0.00 | -82.47% | — | — | — |
ADC Therapeutics S.A. (ADCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ADC Therapeutics S.A. (ADCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 2, 2026·SEC
Jun 24, 2026·SEC
Get notified when ADCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADC Therapeutics S.A. (ADCT) stock FAQ — growth, dividends, profitability & financials explained
ADC Therapeutics S.A. (ADCT) reported $78.8M in revenue over the trailing twelve months. Revenue was $81.4M in fiscal year 2025. That is 4412% more than the $1.8M of fiscal year 2017.
ADC Therapeutics S.A. (ADCT) grew revenue by 2.0% over the trailing twelve months, compared with the twelve months before.
No. ADC Therapeutics S.A. (ADCT) reported a net loss of $96.9M over the trailing twelve months.
ADC Therapeutics S.A. (ADCT) had negative free cash flow of $102.3M over the trailing twelve months.
